Pain

The approval, which is for 4 mg naloxone hydrochloride nasal spray, marks the first OTC, nonprescription approval for a naloxone nasal spray and allows the product to be sold directly to consumers in a variety of retail locations well as online.

The comparative safety and effectiveness of analgesic medications for acute non-specific low back pain are unclear, highlighting the need for higher quality randomized controlled trials comparing different medications.

Electroacupuncture also resulted in a greater relief for the majority of OIC symptoms and improved the quality of life for this patient population and had no effects on cancer pain and its opioid treatment dosage.

An international review of data show certain antidepressants may benefit conditions like fibromyalgia, but many trials are actually inconclusive.

Abbott's Proclaim XR spinal cord stimulation system allows patients with painful diabetic peripheral neuropathy to improve quality of life using a system that is easily incorporated into their everyday lives.

“The fact that patients report substituting cannabis for pain medications so much underscores the need for research on the benefits and risk of using cannabis for chronic pain,” investigators stated.

Based on the identified biomarkers, it was possible to distinguish patients with a good predictive value for pain, sleep, and anxiety.

A cohort study aimed to examine the risk of overdose when treating patients with benzodiazepines compared with alternative therapies for sleep disorders, specifically in young people.

Neither intervention group demonstrated any significant improvements in intensity of chronic breathlessness after taking regular, low-dose, extended-release morphine.

After undergoing arthroscopic knee or shoulder surgery, patients treated with an opioid-sparing postoperative pain management protocol had reduced opioid use compared with standard treatment.

Dr. Craig Granowitz of Lexicon Pharmaceuticals details the success of the LX9211 clinical trial for painful diabetic neuropathy and the unique study design.

LX9211 is a potent, orally delivered, selective small molecule inhibitor of adaptor-associated kinase 1 (AAK1).

CDC investigators stated that the expansion of telehealth strategies is “urgently needed” to provide medications for opioid use disorder because it could increase retention in care and improve outcomes for OUD.

A recent study developed framework to improve fall prevention methodology across the country’s primary health care system.

Reductions in prescribed benzodiazepines were especially noted in continuing prescriptions.

New comparative effectiveness data go against CDC recommendations for tapering or abruptly ending long-term opioid prescription.

FDA approved combination therapy relugolix, estradiol, and norethindrone acetate (Myfembree) for the management of moderate to severe pain associated with endometriosis.

After March 2020, overdose deaths not involving methadone continued to increase whereas methadone-involved overdose deaths remained stable.

According to a new report from the CDC, as fatal drug overdoses increase across the board, the Black and Indigenous communities represent a significantly greater death rates.

Data suggest continued prescribing, not initial prescribing, is linked to opioid addiction risk among exposed family members.

Data indicate that higher levels of perceived pain related disability and greater difficulty falling asleep was associated with increased anxiety levels in adults with fibromyalgia and insomnia.

Intravenous opioid use for VOC decreased by 52% in inpatient services between 2017-2018, while oral opioid use increased.

The study objective was to determine if actigraphy could serve as a complementary clinical tool for sleep evaluation in patients with rheumatoid arthritis.

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.

Presence of chronic liver disease, prior use of gabapentin and being discharged to a long-term hospital or rehabilitation center are among some of the factors associated with a new opioid use disorder diagnosis.

The daily oral combination therapy will be reconsidered for treating endometriosis pain this August.

The completion of this study concluded the planned clinical development program for nasal nalmefene and the company expects to file a New Drug Application in the second half of 2022.

A new method of opioid disposal was proposed by the FDA in an attempt to mitigate unauthorized access to opioids and lessen risk of addiction.

Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients undergoing a bunionectomy.

Outside of the ankle, knees and elbows were also commonly affected joints for patients with hemophilia.